Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge University to Use Affy, ParAllele Tech in Diabetes Genotyping Study

NEW YORK, July 20 (GenomeWeb News) - A team of researchers at Cambridge University will use technology from Affymetrix and ParAllele in a study that will eventually genotype 20,000 type 1 diabetes patients, the companies said today.


The Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory at Cambridge will initially use Affy's GeneChip Tag Arrays and ParAllele's MegAllele genotyping reagents to compare genotypes between 1,000 control samples and 1,000 diabetic samples. The researchers will use ParAllele's standard panel of 10,000 non-synonymous SNPs for this phase of the study.


Eventually, the project will analyze more than 20,000 DNA samples that have already been collected from diabetes patients and their relatives, the companies said.


The project is the first that Affymetrix and ParAllele have jointly signed since they entered into a distribution agreement in May.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.